PharmaRadar360

PharmaRadar360

OncologyDrug intelligence

Enhertu

Trastuzumab Deruxtecan

HER2-directed antibody-drug conjugate. Developed by Daiichi Sankyo. Clinical, regulatory, and source evidence are connected below.

Company
Daiichi Sankyo
Target / MOA
HER2 路 ERBB2
Aliases
Enhertu 路 DS-8201 路 T-DXd
Signals
21
Clinical trials
20
Approvals
1
Evidence sources
21

Latest signals

What changed

The three most recent source-backed changes linked to this drug.

clinical trialClinicalTrials.gov

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Phase 2 路 RECRUITING 路 NRG Oncology

clinical trialClinicalTrials.gov

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1 路 SUSPENDED 路 National Cancer Institute (NCI)

clinical trialClinicalTrials.gov

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

Phase 2 路 SUSPENDED 路 National Cancer Institute (NCI)

Clinical trials

Key active studies

A focused view of recently updated studies 路 20 linked records.

Phase 2RECRUITINGNCT05408845

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NRG Oncology 路 Updated Apr 3, 2026

Phase 1SUSPENDEDNCT05372614

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 2SUSPENDEDNCT04616560

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 1RECRUITINGNCT04704661

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 1RECRUITINGNCT07137416

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Phase 2RECRUITINGNCT06311214

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI) 路 Updated Apr 3, 2026

Regulatory timeline

Approvals and agency activity

Verified regulatory records in reverse chronological order.

ENHERTU

Source evidence

Where this profile comes from

Facts link back to original registries, regulators, labels, and publishers. Counts change as source records update.

ClinicalTrials.govofficial 路 Latest Apr 3, 202620FDAofficial 路 Latest Apr 5, 20241
Professional referenceThis profile summarizes linked public evidence. It is not medical, legal, regulatory, or investment advice. Verify decisions against original sources.